Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
NATACYN
Overview
What is NATACYN?
NATACYN (natamycin ophthalmic suspension) 5% is a sterile, antifungal drug for topical ophthalmic administration. Each mL of the suspension contains: natamycin 5% (50 mg). benzalkonium chloride 0.02%. sodium hydroxide and/or hydrochloric acid (neutralized to adjust the pH), purified water.
The active ingredient is represented by the chemical structure:
Established name: Natamycin
Molecular Formula: CHNO
Molecular Weight: 665.73
Chemical name: Stereoisomer of 22-[(3-amino-3,6-dideoxy- β-D-mannopyranosyl)oxy]-1,3,26- trihydroxy-12- methyl-10-oxo-6,11,28- trioxatricyclo[22.3.1.05,7] octacosa-8,14,16,18,20-pentaene-25- carboxylic acid.
Other: Pimaricin
The pH range is 5.0 - 7.5.
What does NATACYN look like?
What are the available doses of NATACYN?
Sorry No records found.
What should I talk to my health care provider before I take NATACYN?
Sorry No records found
How should I use NATACYN?
NATACYN (natamycin ophthalmic suspension) 5% is indicated for the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms including keratitis. As in other forms of suppurative keratitis, initial and sustained therapy of fungal keratitis should be determined by the clinical diagnosis, laboratory diagnosis by smear and culture of corneal scrapings and drug response. Whenever possible the activity of natamycin against the responsible fungus should be determined. The effectiveness of natamycin as a single agent in fungal endophthalmitis has not been established.
SHAKE WELL BEFORE USING. The preferred initial dosage in fungal keratitis is one drop of NATACYN (natamycin ophthalmic suspension) 5% instilled in the conjunctival sac at hourly or two-hourly intervals. The frequency of application can usually be reduced to one drop 6 to 8 times daily after the first 3 to 4 days. Therapy should generally be continued for 14 to 21 days or until there is resolution of active fungal keratitis. In many cases, it may be helpful to reduce the dosage gradually at 4 to 7 day intervals to assure that the replicating organism has been eliminated. Less frequent initial dosage (4 to 6 daily applications) may be sufficient in fungal blepharitis and conjunctivitis.
What interacts with NATACYN?
Sorry No Records found
What are the warnings of NATACYN?
Sorry No Records found
What are the precautions of NATACYN?
Sorry No Records found
What are the side effects of NATACYN?
Sorry No records found
What should I look out for while using NATACYN?
NATACYN (natamycin ophthalmic suspension) 5% is contraindicated in individuals with a history of hypersensitivity to any of its components.
What might happen if I take too much NATACYN?
Sorry No Records found
How should I store and handle NATACYN?
Store original packages at room temperature; avoid excessive heat.NATACYN (natamycin ophthalmic suspension 5%) is a 15mL fill packaged in a 15mL amber glass bottle with a black phenolic closure. A flint glass dropper with a red plastic closure and a black rubber bulb are packaged separately in a clear plastic blister with Tyvek backing.NDC STORAGE: Do not freezeRx Only© 2000, 2007, 2009, 2016 NovartisRevised: May 20169013293-0516NATACYN (natamycin ophthalmic suspension 5%) is a 15mL fill packaged in a 15mL amber glass bottle with a black phenolic closure. A flint glass dropper with a red plastic closure and a black rubber bulb are packaged separately in a clear plastic blister with Tyvek backing.NDC STORAGE: Do not freezeRx Only© 2000, 2007, 2009, 2016 NovartisRevised: May 20169013293-0516NATACYN (natamycin ophthalmic suspension 5%) is a 15mL fill packaged in a 15mL amber glass bottle with a black phenolic closure. A flint glass dropper with a red plastic closure and a black rubber bulb are packaged separately in a clear plastic blister with Tyvek backing.NDC STORAGE: Do not freezeRx Only© 2000, 2007, 2009, 2016 NovartisRevised: May 20169013293-0516NATACYN (natamycin ophthalmic suspension 5%) is a 15mL fill packaged in a 15mL amber glass bottle with a black phenolic closure. A flint glass dropper with a red plastic closure and a black rubber bulb are packaged separately in a clear plastic blister with Tyvek backing.NDC STORAGE: Do not freezeRx Only© 2000, 2007, 2009, 2016 NovartisRevised: May 20169013293-0516NATACYN (natamycin ophthalmic suspension 5%) is a 15mL fill packaged in a 15mL amber glass bottle with a black phenolic closure. A flint glass dropper with a red plastic closure and a black rubber bulb are packaged separately in a clear plastic blister with Tyvek backing.NDC STORAGE: Do not freezeRx Only© 2000, 2007, 2009, 2016 NovartisRevised: May 20169013293-0516NATACYN (natamycin ophthalmic suspension 5%) is a 15mL fill packaged in a 15mL amber glass bottle with a black phenolic closure. A flint glass dropper with a red plastic closure and a black rubber bulb are packaged separately in a clear plastic blister with Tyvek backing.NDC STORAGE: Do not freezeRx Only© 2000, 2007, 2009, 2016 NovartisRevised: May 20169013293-0516NATACYN (natamycin ophthalmic suspension 5%) is a 15mL fill packaged in a 15mL amber glass bottle with a black phenolic closure. A flint glass dropper with a red plastic closure and a black rubber bulb are packaged separately in a clear plastic blister with Tyvek backing.NDC STORAGE: Do not freezeRx Only© 2000, 2007, 2009, 2016 NovartisRevised: May 20169013293-0516NATACYN (natamycin ophthalmic suspension 5%) is a 15mL fill packaged in a 15mL amber glass bottle with a black phenolic closure. A flint glass dropper with a red plastic closure and a black rubber bulb are packaged separately in a clear plastic blister with Tyvek backing.NDC STORAGE: Do not freezeRx Only© 2000, 2007, 2009, 2016 NovartisRevised: May 20169013293-0516
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Natamycin is a tetraene polyene antibiotic derived from . It possesses activity against a variety of yeast and filamentous fungi, including and . The mechanism of action appears to be through binding of the molecule to the sterol moiety of the fungal cell membrane. The polyenesterol complex alters the permeability of the membrane to produce depletion of essential cellular constituents. Although the activity against fungi is dose-related, natamycin is predominantly fungicidal. Natamycin is not effective against gram-positive or gram-negative bacteria. Topical administration appears to produce effective concentrations of natamycin within the corneal stroma but not in intraocular fluid. Systemic absorption should not be expected following topical administration of NATACYN (natamycin ophthalmic suspension) 5%. As with other polyene antibiotics, absorption from the gastrointestinal tract is very poor. Studies in rabbits receiving topical natamycin revealed no measurable compound in the aqueous humor or sera, but the sensitivity of the measurement was no greater than 2 mg/mL.
Non-Clinical Toxicology
NATACYN (natamycin ophthalmic suspension) 5% is contraindicated in individuals with a history of hypersensitivity to any of its components.Caution should be exercised when propranolol is administered with drugs that have an effect on CYP2D6, 1A2, or 2C19 metabolic pathways. Coadministration of such drugs with propranolol may lead to clinically relevant drug interactions and changes on its efficacy and/or toxicity (see in ).
Propafenone has negative inotropic and beta-blocking properties that can be additive to those of propranolol.
Quinidine increases the concentration of propranolol and produces greater degrees of clinical beta-blockade and may cause postural hypotension.
Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with β-blockers such as propranolol.
The clearance of lidocaine is reduced with administration of propranolol. Lidocaine toxicity has been reported following coadministration with propranolol.
Caution should be exercised when administering propranolol with drugs that slow A-V nodal conduction, e.g. digitalis, lidocaine and calcium channel blockers.
Digitalis Glycosides
Calcium Channel Blockers
There have been reports of significant bradycardia, heart failure, and cardiovascular collapse with concurrent use of verapamil and beta-blockers.
Coadministration of propranolol and diltiazem in patients with cardiac disease has been associated with bradycardia, hypotension, high-degree heart block, and heart failure.
ACE Inhibitors
The antihypertensive effects of clonidine may be antagonized by beta-blockers. Propranolol should be administered cautiously to patients withdrawing from clonidine.
Alpha Blockers
Postural hypotension has been reported in patients taking both beta-blockers and terazosin or doxazosin.
Reserpine
Isoproterenol and Dobutamine
Administration of indomethacin with propranolol may reduce the efficacy of propranolol in reducing blood pressure and heart rate.
Antidepressants
Anesthetic Agents
Warfarin
Neuroleptic Drugs
Thyroxine
Alcohol
FOR TOPICAL OPHTHALMIC USE ONLY — NOT FOR INJECTION. Failure of improvement of keratitis following 7-10 days of administration of the drug suggests that the infection may be caused by a microorganism not susceptible to natamycin.
Continuation of therapy should be based on clinical re-evaluation and additional laboratory studies.
Adherence of the suspension to areas of epithelial ulceration or retention of the suspension in the fornices occurs regularly. Use only if the container is undamaged.
The following events have been identified during post-marketing use of NATACYN in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The events, which have been chosen for inclusion due to their seriousness, frequency of reporting, possible causal connection to NATACYN, or a combination of these factors include: allergic reaction, change in vision, chest pain, corneal opacity, dyspnea, eye discomfort, eye edema, eye hyperemia, eye irritation, eye pain, foreign body sensation, parethesia, and tearing.
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
516Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).